

Exploring Clinical and Echocardiographic Factors in EHRA Type 2 Atrial Fibrillation for Predicting Ischaemic Stroke: A Search for Unrevealed Insights

Jessica Putri Natalia Simbolon¹, Sunu Budhi Raharjo¹, Anwar Santoso¹, Lies Dina Liastuti¹, Dony Yugo Hermanto¹, Vienna Rossimaria¹, Armalya Pritazahra¹, Dicky Armein Hanafy¹, Yoga Yuniadi¹

Abstract

Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia in adults. Valvular heart diseases (VHD), regardless of the arrhythmic problems, increase the risk of thromboembolism, which is even higher in those with associated atrial fibrillation. The EHRA (Evaluated Heart valves, Rheumatic or Artificial) classification categorized AF patients with significant VHD into type 1 and type 2. Unfortunately, there is currently very limited data on risk prediction in stroke-related valvular AF, particularly in the Asian population.

Aims: To investigate the clinical and echocardiographic risk factors for ischaemic stroke prediction in patients with EHRA type 2 VHD.

Methods: This retrospective study enrolled 695 AF patients with EHRA type 2 VHD. The data were collected from patients' medical records who met the inclusion and exclusion criteria from 2015 until 2020. The primary outcome was ischaemic strokes within the observation period.

Results: There were 67 ischaemic stroke events (9,6%) of the total sample. Our analysis found that none of the analyzed variables proved to be statistically significant risk factors in predicting the occurrence of ischaemic stroke. The median CHA2DS2-VASc risk prediction in the sample was 3, with an accuracy of AUC 0.502 (CI 95%; 0.429 – 0.576), sensitivity of 56.7%, and specificity of 44.7%.

Conclusion: Based on the parameters analyzed in this study, no factor was statistically well-predictive to predict the ischaemic stroke incidence in EHRA type 2 VHD AF. In addition, the CHA2DS2-VASc accuracy was low in this population. Further exploration is needed to build an accurate ischaemic stroke risk prediction for EHRA type 2 VHD.

(Indonesian J Cardiol. 2023;44:87-94)

Keywords: Atrial fibrillation, ischaemic stroke, valvular heart disease.

¹ Division of Arrhythmia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia / National Cardiovascular Center Harapan Kita, Jakarta 11420, Indonesia.

Correspondence:

Sunu Budhi Raharjo, Division of Arrhythmia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia / National Cardiovascular Center Harapan Kita, Jakarta 11420, Indonesia.
Email: sunu.b.raharjo@gmail.com

Introduction

Atrial fibrillation (AF) is the most common arrhythmia in adults affecting approximately 2 - 4% of the population worldwide.¹⁻³ Patients with AF have an increased risk for thromboembolism. CHA2DS2-VASc (congestive heart failure or left ventricular disease, hypertension, age > 75 years old, diabetes, stroke (doubled), vascular disease, age > 65 years old, female sex) score has been widely used to predict thromboembolism in patients with non-valvular AF. However, the latest consensus from the European Heart Rhythm Association and the European Society of Cardiology (ESC) no longer used the terminology of non-valvular AF as it was deemed outdated. The consensus then divided AF into two classifications, which are the EHRA (Evaluated Heart valves, Rheumatic or Artificial) type 1 and type 2, which only consisted of patients with valvular AF.⁴ Study by Lip et al. (2018) discovered that the predictive value of thromboembolism of CHA2DS2-VASc score in the EHRA type 1 VHD group was modest, c-indexes 0,62 (0,55-0,7) within one year and 0,66 (0,61-0,72) within 2.5 years follow up.⁵ While the predictive value in the EHRA type 2 VHD group was modest, c-indexes 0,63 (0,60-0,65) within one year and 0,62 (0,60-0,64) within 2.5 years follow up. These findings implied that the CHA2DS2-VASc scoring system was inappropriate for predicting thromboembolism in valvular AF.⁶⁻⁸ VHD, with or without AF, is already a high risk for thromboembolism, which increases even more in patients with AF. Therefore, a different scoring system is needed to provide a more accurate prediction of ischaemic stroke in patients with valvular AF.⁹⁻¹⁰ Previous study showed that hypertension and glomerular filtration rate (GFR) were associated with ischaemic stroke in EHRA type 1 VHD.¹¹ Unfortunately, there is still insufficient information regarding the correlation between these parameters and the incidence of ischaemic stroke in EHRA type 2 VHD. Therefore, this study aims to investigate the clinical and echocardiographic risk factors for ischaemic stroke prediction in patients with EHRA type 2 VHD.

Methods

Our study conducted a retrospective cohort study and recruited patients with AF EHRA type 2 VHD at the National Cardiovascular Center Harapan Kita (NCCHK) hospital, Jakarta, Indonesia, from January 1, 2015, to July 31, 2020. Data were collected from patients' medical records. Ethical clearance was received from the Research Ethics Committee / Institutional Review Board of National Cardiovascular Center Harapan Kita with the number LB.02.01/VII/541/KEP030/2021. Inclusion criteria were adult patients (age > 18 years old) with AF EHRA type 2 VHD who were on direct anticoagulants or vitamin K antagonists. Exclusion criteria were patients with patent foramen ovale (PFO) based on echocardiography, patients with ischaemic stroke who did not have echocardiography and clinical data within one year prior to the stroke event, and patients with periprocedural stroke. Incidence of ischaemic stroke was defined as a stroke that occurred after the patient was diagnosed with AF. The clinical and echocardiographic parameters were age, sex, body mass index, atrial fibrillation type, CHA2DS2-VASc score, hypertension, diabetes mellitus, history of stroke, history of an acute coronary syndrome, history of coronary artery disease, smoking, heart failure, consumption of statin, anti-platelet, warfarin, direct anticoagulant, left ventricular ejection fraction, TAPSE, left atrial diameter, hemoglobin, hematocrit, creatinine, GFR, and time-in-therapeutic range (TTR).

After data collection, we analyzed the association between clinical and echocardiographic parameters with the incidence of ischaemic stroke in patients with AF EHRA type 2 by performing bivariate analysis using Chi-square. Based on the bivariate analysis, variables with a p-value of < 0.25 were further included in the multivariate analysis. Logistic regression using backward selection was employed in multivariate analysis. The final model formulation included variables with p<0.05 from the multivariate analysis. In the final model, good calibration was defined as a p-value of > 0.05 in the Hosmer and Leeshawn calibration test. Good discrimination was described as an area under the curve (AUC) greater than or equal to the expected AUC (>0.65).

Table 1. Baseline characteristic.

| Variables | Ischaemic Stroke | Non-Ischaemic Stroke |
|--|--------------------|----------------------|
| Sex | | |
| Male [n(%)] | 37 (55.2) | 328 (52.2) |
| Female [n(%)] | 30 (44.8) | 300 (47.8) |
| Body Mass Index | | |
| BMI \geq 25 kg/m ² [n(%)] | 13 (25) | 157 (32.7) |
| BMI < 25 kg/m ² [n(%)] | 39 (75) | 323 (67.3) |
| AF Type | 52 | 491 |
| Non-paroxysmal [n(%)] | (77.6) | (78.2) |
| Paroxysmal [n(%)] | 15 (22.4) | 137 (21.8) |
| Hypertension [n(%)] | 48 (71.6) | 392 (62.4) |
| Diabetes mellitus [n(%)] | 17 (25.4) | 167 (26.6) |
| History of stroke [n(%)] | 0 (0) | 33 (5.3) |
| History of coronary heart disease [n(%)] | 8 (11.9) | 96 (15.3) |
| History of acute coronary syndrome [n(%)] | 8 (11.9) | 88 (14) |
| History of Peripheral artery disease [n(%)] | 1 (1.5) | 6 (1) |
| smoking [n(%)] | 13 (19.4) | 140 (22.3) |
| CHA2DS2-VASc score[median (min-max)] | 3 (1-7) | 3 (0-9) |
| Heart Failure [n(%)] | 61 (91) | 593 (94.4) |
| Statin [n(%)] | 21 (31.3) | 210 (33.4) |
| Antiplatelet [n(%)] | 21 (31.3) | 162 (25.8) |
| Warfarin[n(%)] | 54(80.6) | 521 (83) |
| Direct antikoagulant [n(%)] | 0 (0) | 28 (4.5) |
| Left ventricular ejection fraction (LVEF) b (%) [median (min-max)] | 56 (18-87) | 55 (12-89) |
| TAPSEc (mm) [median (min-max)] | 15 (6-30) | 15 (4-35) |
| Left atrial diameter d (mm) [median (min-max)] | 46,5 (25-83.3) | 47 (17-106) |
| Hemoglobin (g/dL) [median (min-max)] | 13 (8.7-17) | 13 (4.5-21.5) |
| Hematocrite (%) [median (min-max)] | 38.3 (25-50,1) | 38,9 (13.3-63.1) |
| Serum Creatinine (mg/dL) [median (min-max)] | 1.07 (0.54 – 6.41) | 1,09 (0,14 – 24,8) |
| GFR (mL/min/1,73 m2) [median (min-max)] | 71 (7-188) | 66 (0.78-329) |
| TTRe (%) [median (min-max)] | 3.5 (0-60.7) | 5.8 (0-100) |

a: missing data 23.5%; b: missing data 0.6%; c: missing data 0.9%; d: missing data 7.2%; e: missing data: 33.4%. AF = atrial fibrillation, TAPSE= Tricuspid Annular Plane Systolic Excursion, GFR = glomerular filtration rate, TTR = Time in Therapeutic Range.

Table 2. Chi-square analysis on clinical history variables.

| Variables | Ischaemic stroke | | | | P | OR | Confidence Interval 95% | |
|--------------------------------------|------------------|-------|-----|------|-------|-------|-------------------------|--------|
| | N | Yes % | N | No % | | | Min | Max |
| Age | | | | | | | | |
| ≥ 54 years | 35 | 52.2 | 330 | 52.5 | 0.962 | 0.988 | 0.596 | 1.635 |
| < 54 years | 32 | 47.8 | 298 | 47.5 | | | | |
| Sex | | | | | | | | |
| Male | 37 | 55.2 | 328 | 52.2 | 0.641 | 1.128 | 0.680 | 1.872 |
| Female | 30 | 44.8 | 300 | 47.8 | | | | |
| Body mass index | | | | | | | | |
| ≥ 25 kg/m ² | 13 | 25 | 157 | 32.7 | 0.258 | 0.686 | 0.356 | 1.322 |
| < 25 kg/m ² | 39 | 75 | 323 | 67.3 | | | | |
| AF type | | | | | | | | |
| Non-paroxysmal | 52 | 77.6 | 491 | 78.2 | 0.914 | 1.034 | 0.565 | 1.893 |
| Paroxysmal | 15 | 22.4 | 137 | 21.8 | | | | |
| Hypertension | | | | | | | | |
| Yes | 48 | 71.6 | 392 | 62.4 | 0.137 | 1.521 | 0.873 | 2.650 |
| No | 19 | 28.4 | 236 | 37.6 | | | | |
| Diabetes mellitus | | | | | | | | |
| Yes | 17 | 25.4 | 167 | 26.6 | 0.830 | 0.939 | 0.527 | 1.673 |
| No | 50 | 74.6 | 461 | 73.4 | | | | |
| History of coronary heart disease | | | | | | | | |
| Yes | 8 | 11.9 | 96 | 15.3 | 0.465 | 0.751 | 0.348 | 1.622 |
| No | 59 | 88.1 | 532 | 84.7 | | | | |
| History of acute coronary syndrome | | | | | | | | |
| Yes | 8 | 11.9 | 88 | 14 | 0.640 | 0.832 | 0.384 | 1.801 |
| No | 59 | 88.1 | 540 | 86 | | | | |
| History of Peripheral artery disease | | | | | | | | |
| Yes | 1 | 1.5 | 6 | 1 | 0.676 | 1.571 | 0.186 | 13.246 |
| No | 66 | 98.5 | 622 | 99 | | | | |
| Smoking | | | | | | | | |
| Yes | 13 | 19.4 | 140 | 22.3 | 0.587 | 0.839 | 0.445 | 1.582 |
| No | 54 | 80.6 | 488 | 77.7 | | | | |
| CHA2DS2-VASc | | | | | | | | |
| ≥ 3 | 38 | 56.7 | 347 | 55.3 | 0.819 | 1.061 | 0.638 | 1.764 |
| < 3 | 29 | 43.3 | 281 | 44.7 | | | | |
| Heart Failure | | | | | | | | |
| Yes | 61 | 91 | 593 | 94.4 | 0.264 | 0.6 | 0.243 | 1.484 |
| No | 6 | 9 | 35 | 5.6 | | | | |
| Statin | | | | | | | | |
| Yes | 46 | 68.7 | 418 | 66.6 | 0.729 | 1.1 | 0.640 | 1.892 |
| No | 21 | 31.3 | 210 | 33.4 | | | | |
| Antiplatelet | | | | | | | | |
| Yes | 46 | 68.7 | 466 | 74.2 | | | | |
| No | 21 | 31.3 | 162 | 25.8 | 0.327 | 0.761 | 0.441 | 1.315 |
| Warfarin | | | | | | | | |
| Yes | 13 | 19.4 | 107 | 17 | | | | |
| No | 54 | 80.6 | 521 | 83 | 0.626 | 1.172 | 0.618 | 2.224 |
| Direct Anticoagulant | | | | | | | | |
| Yes | 67 | 100 | 600 | 95.5 | | | | |
| No | 0 | 0 | 28 | 4.5 | 0.099 | 1.112 | 1.084 | 1.140 |

Table 3. Chi-square analysis on echocardiographic and laboratory variables.

| Variables | Ischaemic stroke | | | | P | OR | Confidence Interval 95% | |
|------------------------------------|------------------|-------|------|------|-------|-------|-------------------------|--------|
| | N | Yes % | No N | % | | | Min | Max |
| Left ventricular ejection fraction | | | | | | | | |
| < 30% | 17 | 25.4 | 110 | 17.6 | 0.120 | 1.589 | 0.883 | 2.859 |
| ≥ 30% | 50 | 74.6 | 514 | 82.4 | | | | |
| TAPSE | | | | | | | | |
| < 17 mm | 41 | 61.2 | 385 | 61.9 | 0.910 | 0.971 | 0.579 | 1.628 |
| ≥17 mm | 26 | 38.8 | 237 | 38.1 | | | | |
| Left atrial diameter | | | | | | | | |
| ≥ 46 mm | 34 | 53.1 | 330 | 56.8 | 0.574 | 0.862 | 0.514 | 1.447 |
| < 46 mm | 30 | 46.9 | 251 | 43.2 | | | | |
| Haemoglobin | | | | | | | | |
| ≥ 12 g/dL | 44 | 65.7 | 439 | 69.9 | 0.474 | 0.824 | 0.484 | 1.403 |
| < 12 g/dL | 23 | 34.3 | 189 | 30.1 | | | | |
| Hematocrit | | | | | | | | |
| ≥ 38% | 36 | 53.7 | 355 | 56.5 | 0.661 | 0.893 | 0.539 | 1.480 |
| < 38% | 31 | 46.3 | 273 | 43.5 | | | | |
| Creatinine Serum | | | | | | | | |
| ≥ 1.35 mg/dL | 20 | 29.9 | 187 | 29.8 | 0.990 | 1.004 | 0.579 | 1.740 |
| < 1.35 mg/dL | 47 | 70.1 | 441 | 70.2 | | | | |
| GFR | | | | | | | | |
| <15 mL/min/1.73m2 | 2 | 3 | 5 | 0.8 | 0.088 | 0.834 | 0.729 | 20.155 |
| ≥15 mL/min/1.73m2 | 65 | 97 | 623 | 99.2 | | | | |
| TTR | | | | | | | | |
| <50% | 42 | 93.3 | 370 | 88.9 | 0.364 | 1.741 | 0.519 | 5.841 |
| >50% | 3 | 6.7 | 46 | 11.1 | | | | |

Notes: Data was analysed with multiple logistic regression with backward method. (*) Variable was significant if P value <0,05. Nagelkerke R2 = 0.318

Table 4. Chi-square analysis on echocardiographic and laboratory variables.

| Variables | P | OR | Confidence Interval 95% | |
|------------------------|-------|-------|-------------------------|---------|
| | | | Minimum | Maximum |
| Hypertension | 0.136 | 1.526 | 0.876 | 2.659 |
| LVEF <30% | 0.213 | 1.463 | 0.804 | 2.663 |
| GFR < 15 mL/min/1.73m2 | 0.123 | 3.584 | 0.672 | 19.105 |

LVEF = left ventricular ejection fraction, GFR = glomerular filtration rate.

Table 5. ROC curve of CHA2DS2-VASc in this population.

| Area | Std. Error | Asymptotic Sig. | Asymptotic 95% Confidence Interval | |
|-------|------------|-----------------|------------------------------------|-------------|
| | | | Lower Bound | Upper Bound |
| 0,502 | 0,037 | 0,948 | 0,429 | 0,576 |

Results:

At the beginning of the study, 1507 patients with valvular AF in NCCHK hospital were recruited between 1 January 2015 and 31 July 2020. Of these,

765 patients had EHRA type 1, four had PFO, three had periprocedural ischaemic strokes, and 40 had non-complete medical records. Thus, a total of 695 patients were included. The baseline characteristic of the study is described in **Table 1**. Ischaemic stroke was reported in




Figure 1. ROC curve of CHA2DS2-VASc in this population.

67 (9.6%) patients during the follow-up period.

For the statistical analysis, we performed a Chi-square analysis for categorical variables. To ensure accuracy and consistency, we converted any numerical variables into categorical ones before conducting the analysis. Cut-off value determination used ROC analysis to divide patients into two groups of categorical variables. From the bivariate Chi-square analysis, we found that several variables were statistically associated with the incidence of ischaemic stroke, in which they had a p-value of < 0.25 . These were hypertension ($p=0.137$), history of stroke ($p=0.055$), no consumption of direct anticoagulant ($p=0.099$), LVEF ($p=0.120$), GFR < 15 mL/minute/1.73 m² ($p = 0.088$), and TTR $< 50\%$ ($p=0.364$), as shown in **Table 2.** and **Table 3.** Then, we performed a multivariate analysis with these variables and found that there was no variable associated with ischaemic stroke as none variable had a p-value of < 0.05 , as shown in **Table 4.** Therefore, the model formulation was not performed.

We evaluated the sensitivity and specificity of CHA2DS2-VASc in this demographic by utilizing the ROC curve, and it revealed the scoring system had 56.7% sensitivity and 44.7% specificity, as shown in **Figure 1** and **Table 5.**

Limitation

The study has several limitations. Firstly, the study had incomplete medical record data due to retrospective sampling. The analysis did not include dyslipidemia because of incomplete data. The second limitation of this study is that we did not analyze the type of VHD as a predictor factor of ischaemic stroke. This is due to the fact that most of the patients in the study had mixed valvular involvement. Third, the definition of 'stroke incidence' in this study referred to the cases of stroke that had been recorded and reported in NCCHK hospital. It should be noted that any incidents of stroke that occurred outside of NCCHK hospital were not included in this definition.

Conclusion:

After a thorough analysis of risk factors, encompassing clinical, echocardiographic, and laboratory data, we found that none of these factors exhibits a statistically high degree of predictivity with respect to ischaemic stroke incidence in EHRA type 2 VHD AF. Further investigations, particularly prospective cohort studies, are needed to confirm the results of this study.

Acknowledgments:

There was no specific funding received for this study. We acknowledge the contribution of the research assistants who supported the data collection of the OneAF registry: Beta Ilhami and Maulaa Putri.

Conflicts Of Interest:

The author declares no conflict of interest.

Declarations:

- **Approval of the research protocol:** The study protocol was approved by the Institutional Review Board of Harapan Kita National Cardiac Center in accordance with the Nuremberg Code and Helsinki Declaration (No. LB.02.01/VII/541/KEP030/2021).
- **Informed Consent:** N/A
- **Registry and the Registration No. of the study/trial:** ClinicalTrials.gov ID NCT04222868
- **Animal Studies:** N/A

References

1. Killu AM, Granger CB, Gersh BJ. Risk stratification for stroke in atrial fibrillation: A critique. *Eur Heart J*. 2019;40(16):1294–302.
2. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: *A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart R. J Am Coll Cardiol*. 2019;74(1):104–32.
3. Lip GYH, Collet JP, Caterina R De, Fauchier L, Lane DA, Larsen TB, et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working. *Europace*. 2017;19(11):1757–8.
4. Lip GYH, Jensen M, Melgaard L, Skjøth F, Nielsen PB, Larsen TB. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: Evaluating “valvular heart disease” in a nationwide cohort study. *Europace*. 2019;21(1):33–40.
5. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: A joint consensus document of the Europ. *Europace*. 2019;21(2):192–3.
6. Kusumoto FM, Bailey KR, Chaouki AS, Deshmukh AJ, Gautam S, Kim RJ, et al. Systematic Review for the 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Pract. *J Am Coll Cardiol*. 2018;72(14):1653–76.
7. Van Den Ham HA, Klungel OH, Singer DE, Leufkens HGM, Van Staa TP. Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation: Results From a National Primary Care Database. *J Am Coll Cardiol*. 2015;66(17):1851–9.
8. Jame S, Barnes G. Stroke and thromboembolism prevention in atrial fibrillation. *Heart*. 2020;106(1):10–7.
9. Doi K, Ogawa H, Ishigami K, Ikeda S, Aono Y, Hamatani Y, et al. Impact of valvular heart disease on mortality, thromboembolic and cardiac events in Japanese patients with atrial fibrillation - the Fushimi AF registry -. *Circ J*. 2020;84(5):714–22.
10. Bisson A, Bodin A, Clementy N, Bernard A, Babuty D, Lip GYH, et al. Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the Ehra valvular heart disease classification. *International Journal of Cardiology*. 2018;260:93–8. doi:10.1016/j.ijcard.2018.03.017
11. Winanti R, Raharjo SB, Ariani R, Hanafy DA, Atmadikoesoemah CA, Almazini P. OR41. hypertension and abnormal renal function increased the risk of ischemic stroke in anticoagulated EHRA type-1 valvular atrial fibrillation. *European Heart Journal Supplements*. 2021;23 (Supplement_F). doi:10.1093/eurheartjsupp/suab122.040
12. Vemulapalli S, Hellkamp AS, Jones WS, Piccini JP, Mahaffey KW, Becker RC, et al. Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the rocket AF trial. *American Heart Journal*. 2016;178:74–84. doi:10.1016/j.ahj.2016.05.001
13. Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, et al. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: Results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. *J Am Heart Assoc*. 2015;4(12):1–8.
14. Sartipy U, Dahlström U, Fu M, Lund LH. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. *JACC Hear Fail*. 2017;5(8):565–74.
15. Son MK, Park JJ, Lim NK, Kim WH, Choi DJ. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction. *Heart*. 2020;106(15):1160–8.
16. Song Z, Xu K, Hu X, Jiang W, Wu S, Qin M, et al.

- A Study of Cardiogenic Stroke Risk in Non-valvular Atrial Fibrillation Patients. *Front Cardiovasc Med.* 2020;7(November):1–7.
17. Pokorney SD, Black-Maier E, Hellkamp AS, Friedman DJ, Vemulapalli S, Granger CB, et al. Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease. *J Am Coll Cardiol.* 2020;75(11):1299–308.
 18. Hart RG, Eikelboom JW, Brimble KS, McMurry MS, Ingram AJ. Stroke prevention in atrial fibrillation patients with chronic kidney disease. *Canadian Journal of Cardiology.* 2013;29(7). doi:10.1016/j.cjca.2013.04.005
 19. Gaikwad T, Ghosh K, Shetty S. VKORC1 and CYP2C9 genotype distribution in Asian countries. *Thrombosis Research.* 2014;134(3):537–44. doi:10.1016/j.thromres.2014.05.028
 20. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. *Thromb Haemost.* 2011;106(5):968–77.
 21. Suriapranata IM, Tjong WY, Wang T, Utama A, Raharjo SB, Yuniadi Y, et al. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. *BMC Medical Genetics.* 2011;12(1). doi:10.1186/1471-2350-12-80
 22. Chan PH, Hai JJ, Chan EW, Li WH, Tse HF, Wong ICK, et al. Use of the SAME-TT2R2 score to predict good anticoagulation control with warfarin in Chinese patients with atrial fibrillation: Relationship to ischaemic stroke incidence. *PLoS One.* 2016;11(3):1–9.
 23. Hong KS, Kim YK, Bae HJ, Nam HS, Kwon SU, Bang OY, et al. Quality of anticoagulation with warfarin in Korean patients with atrial fibrillation and prior stroke: A multicenter retrospective observational study. *J Clin Neurol.* 2017;13(3):273–80.